Use of recombinant human growth hormone in children with chronic renal insufficiency: an update.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Growth retardation is common in children with chronic renal insufficiency (CRI).

Now that dialysis and renal transplantation (TX) have become life sustaining, permanent stunted growth and adult short stature often occurs.

Who Took Part

The abstract describes 8 patients taking part.

The age groups tagged for this paper are young children, children and teenagers, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

What Was Measured

Topics PubMed links to this paper include Growth, Growth Disorders, Growth Hormone, Kidney Failure, Chronic, Kidney Transplantation and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.